ACERCA DE ESTE EPISODIO
Prof Noel Clarke and Dr Bertrand Tombal
Prof Noel Clarke (The Christie Hospital, Manchester, UK) and Dr Bertrand Tombal (Saint-Luc Hospital, Brussels, Belgium) discuss the evolving treatment landscape in prostate cancer for ecancertv at ECC 2015, with a particular focus on new data and dialogue arising from the conference.
They first comment on the potential of TAK-385, a new oral gonadotropin-releasing hormone antagonist. Phase II study findings presented at the meeting showed that it had a good efficacy and safety profile and might thus offer an alternative to existing GnRH androgen deprivation therapies that currently have to be injected.
They also discuss new findings on neoadjuvant therapy for patients undergoing prostatectomy and the results of the STAMPEDE trial. The STAMPEDE trial looked at using docetaxel, zoledronic acid, or both, versus standard of care for hormone-naïve, high-risk, localized or metastatic prostate cancer.
Prof Noel Clarke (The Christie Hospital, Manchester, UK) and Dr Bertrand Tombal (Saint-Luc Hospital, Brussels, Belgium) discuss the evolving treatment landscape in prostate cancer for ecancertv at ECC 2015, with a particular focus on new data and dialogue arising from the conference.
They first comment on the potential of TAK-385, a new oral gonadotropin-releasing hormone antagonist. Phase II study findings presented at the meeting showed that it had a good efficacy and safety profile and might thus offer an alternative to existing GnRH androgen deprivation therapies that currently have to be injected.
They also discuss new findings on neoadjuvant therapy for patients undergoing prostatectomy and the results of the STAMPEDE trial. The STAMPEDE trial looked at using docetaxel, zoledronic acid, or both, versus standard of care for hormone-naïve, high-risk, localized or metastatic prostate cancer.
Inglés
Estados Unidos
TRANSCRIPCIÓN 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
BUSCAR EPISODIOS ANTERIORES
Buscar episodios anteriores de ECC 2015.
OTROS EPISODIOS EN ESTE PODCAST
Prof Mark Lawler - Chair of the EAPM Research Subgroup
Prof Lawler talks to ecancertv at ECC 2015 about his investigation into disparities across Europe.
He discusses what discoveries he has made, and how economics and resources can affect treatment of cancer patients.
Prof Martin Schrappe - University Medical Center Schleswig-Holstein, Kiel, Germany
Prof Schrappe talks to ecancertv at ECC 2015 about improving both the cure rate and the quality of life for survivors of childhood cancers over the next ten years, with the ultimate aim of increasing disease-free an…
Prof Riccardo Audisio - President of the European Society for Surgical Oncology
Prof Audisio talks to ecancertv at ECC 2015 about optimising education about cancer surgery and the need to improve current standards as only 25% of patients receive adequate surgical care.
He also talks about the tre…
Prof Priscilla Brastianos - Massachusetts General Hospital, Boston, USA
Prof Brastianos talks to ecancertv at ECC 2015 about how unravelling the genetic sequences of cancer that has spread to the brain could offer unexpected targets for treatment.
In the interview she highlights the results of a …
Prof Peter Naredi - University of Gothenburg, Gothenburg, Sweden
Prof Naredi talks to ecancertv at ECC 2015 about the use of surgery in synchronous oligometastatic disease.
In the interview he highlights that two to three decades ago it was rare that patients with metastatic disease would be refe…
Descargo de responsabilidad: El podcast y el arte incluidos en esta página son de ecancer.org, que es propiedad de su propietario y no está afiliado ni respaldado por Listen Notes, Inc.
EDITAR
Gracias por ayudar a mantener actualizada la base de datos de podcasts.
